Shi Han Wei
Director/Board Member at Beijing Xiangxin Biotechnology Co., Ltd.
Profile
Shi Han Wei is currently the Director at Beijing Xiangxin Biotechnology Co., Ltd.
and Beijing Meizhong Airui Cancer Hospital Co., Ltd.
He previously worked as a Director at Beijing Amcare Medical Management Co., Ltd.
Shi Han Wei active positions
Companies | Position | Start |
---|---|---|
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | Director/Board Member | 13/11/2019 |
Beijing Meizhong Airui Cancer Hospital Co., Ltd.
Beijing Meizhong Airui Cancer Hospital Co., Ltd. Hospital/Nursing ManagementHealth Services Beijing Meizhong Airui Cancer Hospital Co., Ltd. is a third-level tumor specialist consultation hospital founded in 2017. The company is based in Beijing, China. The hospital offers a variety of tumor expert consultations and has eight major clinic centers, including lung cancer, breast, gynecological tumor, gastrointestinal tumor, hepatobiliary tumor, urinary tumor, tumor consultation, and tumor sieve recovery. Additionally, the hospital has multiple medical technical departments such as tumor radiation images, tumor pathology, tumor radiotherapy, tumor ultrasound, and tumor early screen intervention inspection. | Director/Board Member | 09/04/2020 |
Former positions of Shi Han Wei
Companies | Position | End |
---|---|---|
Beijing Amcare Medical Management Co., Ltd.
Beijing Amcare Medical Management Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Amcare Medical Management Co., Ltd. engages in the sale of medical devices and provision of medical services. Its business activities include medical management consulting, medical technology development, technology consulting, and sale of daily necessities, packaging materials, chemical products, and building materials. The company was founded on October 22, 2012 and is headquartered in Beijing, China. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 3 |
---|---|
Beijing Amcare Medical Management Co., Ltd.
Beijing Amcare Medical Management Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Beijing Amcare Medical Management Co., Ltd. engages in the sale of medical devices and provision of medical services. Its business activities include medical management consulting, medical technology development, technology consulting, and sale of daily necessities, packaging materials, chemical products, and building materials. The company was founded on October 22, 2012 and is headquartered in Beijing, China. | Commercial Services |
Beijing Xiangxin Biotechnology Co., Ltd.
Beijing Xiangxin Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Xiangxin Biotechnology Co., Ltd. was founded in 2018 and is based in the economic-technological development area. The Chinese company has established two R & D centers covering a total area of 5,000 square meters. The company provides comprehensive solutions for cancer precision medicine using genomics technologies, with a focus on next-generation sequencing (NGS) in solid tumors and hematological malignancies. Acornmed has launched over 30 clinical testing products covering early detection and screening of multiple cancers, hereditary cancer identification, companion diagnostics for targeted therapy and immunotherapy, prognostic stratification, longitudinal monitoring of tumors, etc. The company has served more than 500 hospitals and have been endorsed by many clinical oncologists and laboratory professionals. | Health Technology |
Beijing Meizhong Airui Cancer Hospital Co., Ltd.
Beijing Meizhong Airui Cancer Hospital Co., Ltd. Hospital/Nursing ManagementHealth Services Beijing Meizhong Airui Cancer Hospital Co., Ltd. is a third-level tumor specialist consultation hospital founded in 2017. The company is based in Beijing, China. The hospital offers a variety of tumor expert consultations and has eight major clinic centers, including lung cancer, breast, gynecological tumor, gastrointestinal tumor, hepatobiliary tumor, urinary tumor, tumor consultation, and tumor sieve recovery. Additionally, the hospital has multiple medical technical departments such as tumor radiation images, tumor pathology, tumor radiotherapy, tumor ultrasound, and tumor early screen intervention inspection. | Health Services |
- Stock Market
- Insiders
- Shi Han Wei